Archive Newsletter

61. 01.22.26 -- Moving Leukopaks From GTP To GMP Is One Cell Therapy Trend To Watch In '26 1/22/2026
    01/22/26 Cell & Gene Newsletter
62. 01.21.26 -- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026 1/21/2026
    01/21/26 Cell & Gene Newsletter
63. 01.20.26 -- STREAM Edition: Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos 1/20/2026

    01/20/26 Cell & Gene Newsletter

64. 01.20.26 -- Global Shifts And Strategic Resilience Will Shape CGT In 2026 1/20/2026
    01/20/26 Cell & Gene Newsletter
65. 01.19.26 -- Metrics, Not Audits, Should Lead Vendor Accountability 1/19/2026
    01/19/26 Cell & Gene Newsletter
66. 01.16.26 -- Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable 1/16/2026
    01/16/26 Cell & Gene Newsletter
67. 01.15.26 -- Timing Tech Transfer With Complex Raw Materials 1/15/2026
    01/15/26 Cell & Gene Newsletter
68. 01.14.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance 1/14/2026
    01/14/26 Cell & Gene Newsletter
69. 01.13.26 -- STREAM Edition: A 2025 Retrospective Of The Life Science Industry 1/13/2026
    01/13/26 Cell & Gene Newsletter
70. 01.13.26 -- Allogeneic Cell Therapy's Success Hinges On Perfecting The Platform 1/13/2026
    01/13/26 Cell & Gene Newsletter